Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada

Diagnostic Microbiology and Infectious Disease

Volumn 31, Issue 3, 1998, Pages 437-451

  Jones, Ronald N ^a   Ballow, Charles H ^b   Biedenbach, Douglas J ^a   Deinhart, June A ^b   Schentag, Jerome J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MILLARD FILLMORE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALFOPRISTIN PLUS QUINUPRISTIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; CANADA; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0031850635     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)80002-3     Document Type: Article

References (45)

1. Archer G.L., Auger P., Doern G.V., Ferraro M.J., Fuchs P.C., Jorgensen J.H., Low D.E., Murray P.R., Reller L.B., Stratton C.W., Wennersten C.B., Moellering R.C. RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci. Diagn Microbiol Infect Dis. 16:1993;223-226.
2. Arthur M., Reynolds P.E., Depardieu F., Evers S., Dutka-Malen S., Quintiliani R., Courvalin P. Mechanisms of glycopeptide resistance in enterococci. J Infect. 32:1996;11-16.
3. Ballow C.H., Jones R.N., Johnson D.M., Deinhart J.A., Schentag J.J. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis. 29:1997;173-186.
4. Barry A.L., Fuchs P.C., Brown S.D. Provisional interpretive criteria for quinupristin/dalfopristin susceptibility tests. J Antimicrob Chemother. 39:(suppl A):1997;87-92.
5. Bergeron M., Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother. 39:(suppl A):1997;129-138.
6. Biedenbach D., Wanger A., Jones R.N. Comparative in vitro activity of quinupristin/dalfopristin (RP 59500) tested against penicillin- and macrolide-resistant pneumococci by the Etest. J Antimicrob Chemother. 38:1996;553-555.
7. Bonilla H.F., Perri M.B., Kauffman C.A., Zervos M.J. Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium. Diagn Microbiol Infect Dis. 25:1996;127-131.
8. Caron F., Gold H.S., Wennersten C.B., Farris M.G., Moellering R.C. Jr, Eliopoulos G.M. Influence of erythromycin resistance, inoculum growth phase, and incubation time on assessment of the bactericidal actiity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother. 41:1997;2749-2753.
9. Chow J.W., Donabedian S.M., Zervos M.J. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin Infect Dis. 24:1997;90-91.
10. Collins L.A., Malanoski G.J., Eliopoulos G.M., Wennersten C.B., Ferraro M.J., Moellering R.C. In vitro activity of RP 59500, an injectable streptogramin antibiotic, against vancomycin-resistant Gram-positive organisms. Antimicrob Agents Chemother. 37:1993;598-601.
11. Cormican M.G., Jones R.N. Emerging resistance to antimicrobial agents in Gram-positive bacteria. Drugs. 51:(suppl 1):1996;6-12.
12. Doern G.V., Brueggemann A., Holley H.P. Jr, Rauch A.M. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995 Results of a 30-center national surveillance study . Antimicrob Agents Chemother. 40:1996;1208-1213.
13. Ena J., Houston A., Wenzel R.P., Jones R.N. Trends in Gram-positive blood stream organism resistance A seven-year audit of five glycopeptides and other drugs at a large university hospital . J Chemother. 5:1993;17-21.
14. Evans P.A., Norden C.W., Rhoads S., Deobaldia J., Silber J.L. In vitro susceptibilities of clinical isolates of vancomycin-resistant enterococci. Antimicrob Agents Chemother. 41:1997;1406-1410.
15. Fantin B., Leclercq R., Merle Y., Saint-Julien L., Veyrat C., Duval J., Carbon C. Critical influence of resistance to streptogramin B-type antibiotics activity of RP 59500 (quinupristin/dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother. 39:1995;400-405.
16. Fass R.J. In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci and enterococci. Antimicrob Agents Chemother. 35:1991;553-559.
17. Freeman C., Robinson A., Cooper B., Mazens-Sullivan M., Quintiliani R., Nightingale C. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci. Diagn Microbiol Infect Dis. 21:1995;47-50.
18. Goto S., Miyazaki S., Kaneko Y. The in vitro activity of RP 59500 against Gram-positive cocci. J Antimicrob Chemother. 30:(suppl A):1992;25-28.
19. Hiramotsu K., Hanaki H., Ino T., Yabuta K., Oguri T., Tenover F.C. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 40:1997;135-146.
20. Jamjian C., Barrett M.S., Jones R.N. Antimicrobial characteristics of quinupristin/dalfopristin (Synercid® at 30:70 ratio) compared to alternative ratios for in vitro testing. Diagn Microbiol Infect Dis. 27:1997;129-138.
21. Johnson C.C., Slavoski L., Schwartz M., May P., Pitsakis P.G., Shur A.L., Levison M.E. In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagn Microbiol Infect Dis. 21:1995;169-173.
22. Jones R.N., Barrett M.S. Antimicrobial activity of SCH 27899, oligosaccharide member of the everninomycin class with a wide Gram-positive spectrum. J Clin Microbiol Infect. 1:1995;35-43.
23. Jones R.N., Johnson D.M., Erwin M.E. In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones. Antimicrob Agents Chemother. 40:1996;720-726.
24. Jones R.N., Marshall S.A., Pfaller M.A., Wilke W.W., Hollis R.J., Erwin M.E., Edmond M.B., Wenzel R.P. Nosocomial enterococcal blood stream infections in the SCOPE Program Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy . Diagn Microbiol Infect Dis. 29:1997;95-102.
25. Jones R.N., Sader H.S., Erwin M.E., Anderson S.C. Emerging resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagn Microbiol Infect Dis. 21:1995;85-93.
26. Klugman K.P. Epidemiology, control and treatment of multiresistant pneumococci. Drugs. 52:(suppl 2):1996;42-46.
27. Landman D., Quale J.M. Management of infections due to resistant enterococci A review of therapeutic options . J Antimicrob Chemother. 40:1997;161-170.
28. Linden P.K., Pasculle A.W., Manez R., Kramer D.J., Fung J.J., Pinna A.D., Kusne S. Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis. 22:1996;663-670.
29. Moellering R.C. Jr. The Enterococcus A versatile pathogen . J Infect Chemother. 3:1997;1-4.
30. Performance Standards for Antimicrobial Disk Susceptibility Tests-Fifth Edition; Approved Standard. NCCLS Document M2-A5. 1997;NCCLS, Wayne, PA.
31. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically-Third Edition; Approved Standard. NCCLS Document M7-A3. 1997;NCCLS, Wayne, PA.
32. Performance Standard for Antimicrobial Susceptibility Testing. Document M100-S8. 1998;NCCLS, Wayne, PA.
33. Nobel W.C., Virani Z., Cree R.G.A. Cotransfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microb Lett. 93:1992;195-198.
34. Norris A.H., Reilly J.P., Edelstein P.H., Brennan P.J., Schuster M.G. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections. Clin Infect Dis. 20:1995;1137-1144.
35. Panililio A., Culver D.H., Gaynes R.P., Banerjee S., Henderson T.S., Tolson J.S., Martone W.J. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991. Infect Control Hosp Epidemiol. 13:1992;582-586.
36. Pechere J.C. Streptogramins A unique class of antibiotics . Drugs. 51:(suppl 1):1996;13-19.
37. Rende-Fournier R., LeClercq R., Galimand M., Duval J., Courvalin P. Identification of the sat A gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM 4145. Antimicrob Agents Chemother. 37:1993;2119-2125.
38. Rubinstein E., Bompart F. Activity of quinupristin/dalfopristin against Gram-positive bacteria Clinical applications and therapeutic potential . J Antimicrob Chemother. 39:1997;139-143.
39. Sader J.S., Biedenbach D., Jones R.N. Evaluation of Vitek and API 20S for species identification of enterococci. Diagn Microbiol Infect Dis. 22:1995;315-319.
40. Schwalbe R.S., Stapleton J.T., Gilligan P.H. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med. 316:1987;927-928.
41. Vannuffel P., Cocito C. Mechanism of action of streptogramins and macrolides. Drugs. 51:1996;20-30.
42. Verbist L., Verhaegen J. Comparative in vitro activity of RP 59500. J Antimicrob Chemother. 30:(suppl A):1992;39-44.
43. Voss A., Doebbeling B.N. The world-wide prevalence of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents. 5:1995;101-106.
44. Willey BM, Low DE (1997) A simple approach to the correct species identification of Enterococcus faecium and Enterococcus faecalis for epidemiology and quinupristin/dalfopristin treatment purposes. Proceedings of the 4th ICMASK. Barcelona, Spain.
45. Woodford N., Johnson A.P., Morrison D., Speller D.C.E. Current perspectives on glycopeptide resistance. Clin Microbiol Rev. 8:1995;585-615.